Heterocyclic compounds useful as raf kinase inhibitors

Details Heterocyclic compounds useful as raf kinase inhibitors Heterocyclic compounds useful as raf kinase inhibitors

C - Chemistry, Metallurgy

07

D

C07D 413/12 (2006.01) A61K 31/505 (2006.01) A61P 35/00 (2006.01) C07D 413/14 (2006.01) C07D 417/12 (2006.01) C07D 417/14 (2006.01)

Patent

CA 2694284

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Cy1 is an optionally substituted phenyl or an optionally substituted 5-6 membered saturated, partially unsaturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Cy2 is an optionally substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently se-lected ted from nitrogen, oxygen, or sulfur; L1 is a direct bond of an optionally substituted, straight or branched C1-6 alkylene chain; L is a direct bond, or is an optionally substituted, straight or branched C1-6 alkylene chain wherein 1 or 2 methylene units of L2 are optionally and independently replaced by -O-, -S-, -N(R)-, -C(O)-, - C(O)N(R)-, -N(R)C(O)N(R)-, -N(R)C(O)-, -N(R)C(O)O-, -OC(O)N(R)-, -SO2-, -SO2N(R)-, -N(R)SO2-, -OC(O)-, -C(O)O-, or a 3-6 membered cycloalkylene; each R is independently hydro-gen or an optionally substituted C1-6 aliphatic group; The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Cy1 is an optionally substituted phenyl or an optionally substituted 5-6 membered saturated, partially unsaturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Cy2 is an optionally substituted 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms, independently se-lected from nitrogen, oxygen, or sulfur; L1 is a direct bond of an optionally substituted, straight or branched C1-6 alkylene chain; L2 is a direct bond, or is an optionally substituted, straight or branched C1- 6 alkylene chain wherein 1 or 2 methylene units of L2 are optionally and independently replaced by -O-, -S-, -N(R)-, -C(O)-, - C(O)N(R)-, -N(R)C(O)N(R)-, -N(R)C(O)-, -N(R)C(O)O-, -OC(O)N(R)-, -SO2-, -SO2N(R)-, -N(R)SO2-, -OC(O)-, -C(O)O-, or a 3-6 membered cycloalkylene; each R is independently hydro-gen or an optionally substituted C1-6 aliphatic group;

La présente invention porte sur des composés utiles en tant qu'inhibiteurs de la protéine kinase Raf. La présente invention porte également sur les compositions de ceux-ci, et sur des procédés de traitement des maladies à médiation par Raf.

Affiliated with

Also associated with

Rating

Heterocyclic compounds useful as raf kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds useful as raf kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds useful as raf kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1348799